Menu
We focus on the development of repurposed small molecule drugs targeting neurological indications facilitated by our unique, behaviour based zebrafish screening technology.
| ID | Modality | Reg. pathway | Preclinical | Phase I | Phase II | Phase III |
|---|---|---|---|---|---|---|
| 3Z-20-001 | α2/I1 agonist | US NDA EU 2001/83/EC 8(3)/10 |
Zebrafish POC ✓
Rodent POC ✓ |
|||
| 3Z-20-002 | α1 agonist | US 505(b)(2) EU 2001/83/EC 8(3)/10 |
Zebrafish POC ✓ | |||
| 3Z-20-003 | L-type Ca blocker | US 505(b)(2) EU 2001/83/EC 8(3)/10 |
Zebrafish POC ✓
Rodent POC ✓ In silico ✓ |
|||
| 3Z-20-004 | NSAID | US NDA EU 2001/83/EC 8(3)/10 |
Zebrafish POC ✓ | |||
| 3Z-20-005 | I1 agonist | NDA | Zebrafish POC ✓ |